Breast Cancer Metastatic
Conditions
Keywords
breast neoplasm, oligometastases, radiotherapy, stereotactic ablative radiotherapy
Brief summary
More and more evidence suggests that local radiotherapy can improve the outcomes for patients with oligometastatic disease. The purpose of this study is to assess the impact of radiotherapy, compared with standard systemic therapy alone, on survival, local control and toxicities in patients with extracranial oligometastatic breast cancer. Eligible patients are randomized in a 1:2 ratio between the control arm (standard systemic therapy), and the WLRT arm (standard systemic therapy + radiotherapy). Randomization will be stratified by three factors: visceral metastasis (yes vs.no), number of metastases(≤2 vs. \>2), hormone receptor(positive vs. negative). SBRT technique is preferred. During and after radiotherapy, the patients are followed and the efficacy and toxicities of radiotherapy are evaluated.
Interventions
DRUGstandard of care
patients receive appropriate therapy at the discretion of the treating oncologist, i.e. systemic therapy according to molecular subtypes, including chemotherapy, endocrine therapy, targeted therapy, or immunotherapy.
RADIATIONradiotherapy + standard of care
Patients receive radiotherapy to all known metastases. SBRT technique is preferred, especially for metastases in bone, lung and liver. Conventional RT can be used when SBRT is not appropriate, such as metastasis in mediastinal or contralateral supraclavicular nodal regions. Total doses of 30Gy to 50Gy in 5 fractions for SBRT are recommended depending on the tolerance of adjacent normal tissue. Total dose of 60Gy in 25 fractions is recommended for conventional RT. Patients can receive systemic therapy concurrently with RT at the discretion of treating radiation oncologist. After completion of SBRT to all sites of known metastatic disease, patients will continue standard of care therapy per the treating oncologist.
Sponsors
Liaoning Cancer Hospital & Institute
Wuhan University
China-Japan Union Hospital, Jilin University
Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University
West China Hospital
Shanxi Province Cancer Hospital
Peking Union Medical College Hospital
Chinese Academy of Medical Sciences
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* 18-70 years old * ECOG performance status 0-2. * Newly-diagnosed or metachronous extracranial oligometastatic diseases confirmed by pathology or imaging, with or without locoregional disease (biopsy of metastasis is preferred). * Total number of locoregional and metastatic lesions of 1-5 , the maximum diameter of lesions ≤5 cm and at least one lesion could be evaluated by RECIST1.1. * Have received or plan to receive systemic therapy. * All lesions could be safely treated by radiotherapy. * Life expectancy \> 6 months. * Have adequate organ function.
Exclusion criteria
* Have metastases in the central nervous system. * have indications for palliative radiotherapy to reduce symptoms, such as pain, bleeding, obstruction, and pending fractures caused by the tumor. * Have moderate/severe liver dysfunction (Child Pugh B or C) from liver metastases, . * Malignant pleural effusion * Unable to tolerate radiotherapy due to serious comorbidity * Have received prior radiotherapy for target area * Pregnant or lactating women
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression-free Survival | 2 years | Time from randomization to disease progression at any site or death. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Local control rate | 2 years | Incidence of tumor control within RT fields during follow up. |
| Incidence of toxicities | 2 years | Incidence of acute and late toxicities from treatment graded according to radiation therapy oncology group (RTOG) radiation injury criteria and National Cancer Institute CTCAE version 4.0 |
| Overall Survival | 2 years | Time from randomization to death from any cause. |
| Translational exploration | 2 years | Assessment of circulating tumor cells (CTCs), ctDNA, as prognostic and predictive markers of survival, and for early detection of progression. |
| Proportion of acceptable SBRT completion | 2 years | Proportion of patients who completed SBRT with acceptable dose prescriptions |
| Quality of Life measured by the Functional Assessment of Cancer Therapy- General (FACT-G) | 2 years | Assessment of quality of life scores by FACT-G |
Countries
China
Contacts
Primary ContactShu-lian Wang, M.D
Outcome results
None listed